ARK Genomic Revolution ETF ARKG

Medalist Rating as of | See ARK Investment Hub

Morningstar’s Analysis ARKG

Will ARKG outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

ARK Genomic Revolution ETF holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings ARKG

  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 58.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

10x Genomics Inc Ordinary Shares - Class A

9.26 197M
Healthcare

Twist Bioscience Corp

8.65 184M
Healthcare

Tempus AI Inc Class A common stock

8.18 174M
Healthcare

CRISPR Therapeutics AG

5.35 114M
Healthcare

Absci Corp

5.05 108M
Healthcare

Illumina Inc

4.83 103M
Healthcare

Natera Inc

4.65 99M
Healthcare

Guardant Health Inc

4.58 98M
Healthcare

CareDx Inc

4.08 87M
Healthcare

Personalis Inc

3.84 82M
Healthcare

Sponsor Center